No abstract available.
Beauty ; Burns ; Cicatrix

No abstract available.

No abstract available.
Hematoma*

No abstract available.
Neck*

For the evaluation of the left ventricular diastolic function in mild to moderate hypertensive patients without left ventricular hypertrophy, 15 hypertensive patients (group A) and 15 normotensive subjects (group B) were examined by 2-D guided M-mode echocardiography. Various systolic and diastolic indices were derived from computer-assissted analysis of differential curves of left ventricular dimension and posterior wall thickness. The systolic and diastolic function indices of each of the two groups were compared. The results were as follows : 1) There were no significant differences in ejection fraction, left ventricular peak ejection rate and posterior wall thickening rate between two groups. 2) There were no significant differences in % ventricular A wave, left ventricular peak filling rate and posterior wall peak relaxation rate between two groups. 3) One third filling rate was 2.07+/-0.41 EDD/sec in group A and which was significantly lower than 3.29+/-0.88 EDD/sec of group B. Above result suggests that computer-assisted analysis of differential curves of left ventricular dimension and posterior wall thickness could be helpful in the early detection of diastolic dysfunction, and that left ventricular diastolic dysfunction in its early filling period may develop in the mild to moderate hypertensive patients even before left ventricular hypertrophy develops.
Echocardiography ; Humans ; Hypertrophy, Left Ventricular* ; Relaxation

A new angiotensin converting enzyme inhibitor, enalapril, was administered in 20 hypertensive patients (7 mild, 6 moderate and 7 severe hypertensives) for 8 weeks or longer in order to see the blood pressure lowering effects. Additionally the left ventricular mass index was measured by 2-D guided M-mode echocardiography before and after enalapril therapy, and subjective symptoms and laboratory findings were also followed. The results were as follows: 1) After 8 weeks of enalapril treatment (the doses form 10 mg to 20mg once a day) blood pressure were lowered markedly in 10, moderately in 4, mildly in 4 cases, but the blood pressures were not lowered in 2 cases with severe hypertension. The means of the blood pressures of the group were lowered form 182.1+/-19.2 to 148.0+/-26.0mmHg in systolic and from 111.9+/-14.7 to 95.1+/-17.1mmHg in diastolic after 8 weeks of treatment (p<0.001). 2) Heart rates were not changed significantly with enalapril. 3) The symptoms of insomnia and headache were reported to be improved after enalapril in 13 cases. 4) No discernable changes in CBC and serum level of creatinine were observed. But the random urine protein was decreased in 6 cases with proteinuria in routine urinalysis. The serum lipid profile was not significantly changed, but in the 2 cases in which the ratio of total to HDL-cholesterol was above 5.0, the ratio fell to below 5.0. 5) There was no significant EKG change after enalapril. 6) In 9 cases out of 13 cases with the left ventricular mass index (LVMI) above 125g/m2 BSA, LVMI was followed by echocardiography after enalapril. LVMI was significantly decreased in 8 of 9 cases and mean values after enalapril was decreased from 183.1+/-88.0g/m2 BSA to 150.8+/-61.3g/m2 BSA (p<0.0025). 7) Side effects after enalapril administration were transient dizziness in 4 cases and ageusia in 2 cases. Above results suggest that the enalapril could be an initial choice in the treatment of essential hypertension as a single oral agent in once a day regimen resulting in good antihypertensive effects, improvement of subjective symptoms, regreassion of the left ventricular hypertrophy and few side effects.
Ageusia ; Blood Pressure ; Creatinine ; Dizziness ; Echocardiography ; Electrocardiography ; Enalapril* ; Headache ; Heart Rate ; Humans ; Hypertension ; Hypertrophy, Left Ventricular ; Peptidyl-Dipeptidase A ; Proteinuria ; Sleep Initiation and Maintenance Disorders ; Urinalysis

Catopril, an angiotensin converting enzyme inhibitor, was administrated in 30 hypertensive patients(mild 8, moderate 12, severe 10 cases)for 12 weeks or longer in order to observe the hypertensive effects. Changes in quality of life, side effects, electrocardiogram and left ventricular mass index(LVMI) by 2D-guided M-mode echocardiography were also evaluated before and after captopril. 1) After 12 weeks treatment with 25 to 150mg of captopril alone, blood pressures were lowered markedly in 16(53%), moderatly in 5(17%) and midly in 2(7%), while the addition of 25mg hydrochlorthiazide to captopril in the patients who showed no satisfactory responses the blood pressure were lowered markly in 21(70), moderately in 6(20%) and mildly 3(10%) out of 30 patients studied. The average of blood pressure of the 30 subjects were systolic 180.7+/-20.7mmHg(M+/-SD) and diastolic 113.2+/-12.5 before treatment, which were lowered to 148+/-15.8 and 92.5+/-8.0mmHg respectively after 12 weeks(P<0.005). 2) Heart rates were not changed with captopril and/or hydrochlorothiazide. 3) Quality of life improved markedly in 5(17%) and slightly in 12(40%) out of 30 subjects. 4) Complete blood cell count, urinalysis and serum enzymes followed revealed no significant changes. 5) By electrocardiographic follow-up studies 1 out of 13 subjects with LVH, 1 out of 4 LAH, 1 out of 2 ST-T changes were revealed to improved to normal. 6) In 25 out of 30 cases left ventricular mass indices(LVMI) were above 125g/m2 before treatment, among which 15 cases were followed with satisfactoriness good quality of the echocardiographic recorings and the LVMI was reduced from 169.6+/-40.7 to 141.7+/-40.9g/m2(P<0.01). 7) Undesirable side effects were dry cough 3, skin rash 2, dysgeusia 1 and renal dysfunction 1. 8) Considering the blood pressure lowering effects, life quality changed and side effects together the captopril was considered very useful in 8(27%) and useful in 16(53%) out of 30 subjects. Above results suggest that captopril can be prescribed as an effective initial single agent or with in combinations with thiazide for the treatment of hypertensive of various severities with acceptably low side effects.
Blood Cell Count ; Blood Pressure ; Captopril* ; Cough ; Dysgeusia ; Echocardiography ; Electrocardiography ; Exanthema ; Follow-Up Studies ; Heart Rate ; Humans ; Hydrochlorothiazide ; Peptidyl-Dipeptidase A ; Quality of Life ; Urinalysis

No abstract available.
Choanal Atresia*

No abstract available.
Myocardial Stunning*

No abstract available.
Tomography, Emission-Computed, Single-Photon*